Clinical Trial

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Name: Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma — clinical trial record (NCT07233720)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Trial Details

NCT Number	NCT07233720
Lead Sponsor	Henan Cancer Hospital
Conditions	Marginal Zone Lymphoma
Enrollment	30 participants
Start Date	2025-11-18
Primary Completion	2028-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-18